Table 4. Prognostic significance of FGF/FGFR gene amplification and FGFR overexpression in primary and oligometastatic CRC.
| Lesion | Receptor/ ligand | Status | Events/total | Median overall survival in months (95%CI) | Log rank test |
|---|---|---|---|---|---|
| Primary tumors | |||||
| FGFR1 | Amplified | 3/5 | 38 (3-NA) | ||
| non-amplified | 33/73 | NA (42-NA) | P= 0.404 | ||
| FGF 3,4,19 | amplified | 2/2 | 11.5 (10-NA) | ||
| non-amplified | 41/85 | NA (38-NA) | P= 0.059 | ||
| FGFR1 | Overexpression | 7/10 | 28 (7-NA) | ||
| no overexpression | 47/88 | 53 (38-NA) | P= 0.228 | ||
| FGFR2 | Overexpression | 3/5 | 46 (42-NA) | ||
| no overexpression | 47/85 | 53 (28-NA) | P= 0.99 | ||
| FGFR3 | Overexpression | 9/18 | 46 (27-NA) | ||
| no overexpression | 48/92 | 61 (39-NA) | P= 0.985 | ||
| Metastases | FGFR1 | Amplified | 2/2 | 12.6 (5.24-NA) | |
| non-amplified | 15/40 | 47.4 (40.79-NA) | P= 0.00111 | ||
| FGF 3,4,19 | Amplified | 0 | NA | ||
| non-amplified | 24/51 | 41.4 (28.1-NA) | NA | ||
| FGFR1 | Overexpression | 1/4 | NA (22.2-NA) | ||
| no overexpression | 21/43 | 40.8 (28.1-NA) | P= 0.428 | ||
| FGFR2 | Overexpression | 0 | NA | ||
| no overexpression | 21/45 | 41.4 (28.1-NA) | NA | ||
| FGFR3 | Overexpression | 6/7 | 19.9 (15.1-NA) | ||
| no overexpression | 16/40 | 47.4 (40.8-NA) | P= 0.0152 |
Gene amplification was measured by FISH, overexpression by RNA ISH, based on H-score; CI, confidence interval; NA, not available.